| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.
|
Cancer Res
|
2009
|
2.03
|
|
2
|
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.
|
Cancer
|
2004
|
1.90
|
|
3
|
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
|
Cancer
|
2006
|
1.75
|
|
4
|
A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion.
|
Breast Cancer Res
|
2012
|
1.70
|
|
5
|
Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion.
|
Breast Cancer Res
|
2013
|
1.64
|
|
6
|
DNA methylation and breast cancer.
|
Biochem Pharmacol
|
2004
|
1.57
|
|
7
|
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
|
Cancer Res
|
2007
|
1.45
|
|
8
|
Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
|
J Biol Chem
|
2004
|
1.36
|
|
9
|
Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer.
|
Cancer Res
|
2003
|
1.31
|
|
10
|
Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo.
|
Cancer Res
|
2006
|
1.31
|
|
11
|
A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.
|
Mol Cancer Ther
|
2006
|
1.29
|
|
12
|
ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.
|
Cancer Res
|
2007
|
1.23
|
|
13
|
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
|
J Biol Chem
|
2002
|
1.20
|
|
14
|
Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo.
|
Neoplasia
|
2008
|
1.20
|
|
15
|
Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.
|
Cancer Res
|
2002
|
1.14
|
|
16
|
DNA demethylation and cancer: therapeutic implications.
|
Cancer Lett
|
2004
|
1.11
|
|
17
|
An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
|
Cancer Res
|
2002
|
1.05
|
|
18
|
Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
|
Anticancer Drugs
|
2007
|
1.05
|
|
19
|
A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis.
|
Int J Cancer
|
2006
|
1.00
|
|
20
|
Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
|
FASEB J
|
2003
|
0.99
|
|
21
|
SH2B1beta (SH2-Bbeta) enhances expression of a subset of nerve growth factor-regulated genes important for neuronal differentiation including genes encoding urokinase plasminogen activator receptor and matrix metalloproteinase 3/10.
|
Mol Endocrinol
|
2007
|
0.98
|
|
22
|
Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding.
|
Biochem Biophys Res Commun
|
2006
|
0.98
|
|
23
|
A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis.
|
Clin Exp Metastasis
|
2005
|
0.95
|
|
24
|
Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma.
|
Clin Cancer Res
|
2004
|
0.95
|
|
25
|
Role of epigenetics in cancer initiation and progression.
|
Adv Exp Med Biol
|
2011
|
0.93
|
|
26
|
Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling.
|
Anticancer Drugs
|
2006
|
0.90
|
|
27
|
Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer.
|
Anticancer Drugs
|
2005
|
0.86
|
|
28
|
Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications.
|
Curr Cancer Drug Targets
|
2005
|
0.85
|
|
29
|
Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells.
|
Carcinogenesis
|
2004
|
0.85
|
|
30
|
Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer.
|
Oncogene
|
2005
|
0.84
|
|
31
|
A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia.
|
Cancer Res
|
2004
|
0.84
|
|
32
|
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
|
Neoplasia
|
2007
|
0.82
|
|
33
|
Estradiol-dependent regulation of angiopoietin expression in breast cancer cells.
|
J Steroid Biochem Mol Biol
|
2010
|
0.80
|
|
34
|
A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.
|
Int J Oncol
|
2011
|
0.78
|
|
35
|
Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells.
|
Endocrinology
|
2003
|
0.77
|